September 17, 2018 — 4C Medical Technologies Inc. announced that its AltaValve transcatheter mitral valve replacement (TMVR) technology will be highlighted at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, Sept. 21-25, 2018 in San Diego. The technology will be highlighted in the following presentations:
- Friday, Sept. 21, 2018 at 3:45 p.m. during Innovation Sessions:
- "4C Medical's AltaValve: The First Human Experience" by Josep Rodés-Cabau, M.D.;
- Sunday, Sept. 23, 2018 at 3:50 p.m. during Edited Taped Cases:
- "AltaValve TMVR" presented by Rodés-Cabau; and
- Monday, Sept. 24, 2018 at 10:12 a.m. during Didactic Session: Transcatheter Mitral Valve Therapies, Part 2 - TMVR:
- "AltaValve: Device Attributes, Implant Procedure, and First-in-Human" presented by Philippe Généreux, M.D.
Rodés-Cabau is the director of catheterization and interventional laboratories in Quebec Heart and Lung Institute, associate professor of medicine of Laval University and Canadian Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Quebec City, Quebec, Canada).
Généreux is co-director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, N.J.) and a practicing Interventional cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).
In contrast with other TMVR devices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle. Furthermore, due to supra-annular positioning of the valve, AltaValve avoids issues related to the complexity and dynamics of the mitral annulus, making it suitable for patients independent of their MR mechanism.
The AltaValve is a self-expanding device that may be inserted into the left atrium using either a transseptal or a transapical delivery system.
For more information: www.4cmed.com
